Supplemental Table Legends:

Table S1: Selected animal models of Alzheimer's disease

Abbreviations: APP – amyloid precursor protein; CAMKII – calcium/calmodulin-dependent protein kinase II; MAPT – microtubule associated protein tau; PDGF-β – platelet derived growth factor beta; PSEN1 – presenilin 1; TRE – tetracycline operon-responsive element; tTA – tetracycline-controlled transactivator.

S1: Selected animal models of Alzheimer's disease

Model Name	Genes (mutations), Promoter	Selected pathological and behavioral changes	Key References:
Tg2576	• APP (KM670/671NL; Swedish mutation) • Promoter: hamster prion	• First amyloid plaque deposition around 6 months, numerous by 12 months • Absent tangles but hyper-phosphorylated tau present • Absent or minimal neuronal loss • Cognitive impairment as early as 6 months and widespread by 12 months	(Hsiao et al., 1996)
TgCRND8	• APP (KM670/671NL, V717F; Swedish, Indiana Mutation) • Promoter: hamster prion	• Amyloid deposition first at 3 months and progresses with age • Absent tangles but hyper-phosphorylated tau present • Variable cell loss by region with fewer hippocampal neurons at 6 months • Cognitive impairment as early as 3 months	(Chishti et al., 2001)
J20	• APP (KM670/671NL, V717F; Swedish, Indiana Mutation) • Promoter: PDGF-β	• Amyloid deposition progresses with age, first at 5-7 months and widespread by 8-10 months • Absent tangles • Variable cell loss by region with fewer hippocampal CA1 neurons from 3 months • Cognitive impairment as early as 4 months	(Mucke et al., 2000)
APP/PS1	• APP (KM670/671NL; Swedish mutation) • PSEN1 (L166P) • Promoter: Thy1	• Amyloid deposition first at 1.5 months and progresses with age • Phosphorylated tau-positive neuritic process around plaques • Modest neuronal loss in dentate gyrus at 17 months • Cognitive impairments at 7-8 months	(Radde et al., 2006)
3xTg	• APP (KM670/671NL; Swedish mutation) • PSEN1 (M146V) • MAPT (P301L) • Promoter: Thy1.2	• Amyloid deposition first at 6 months and progresses with age • No tau pathology at 6 months, and tau immunoreactivity extensive by 12 months • Unknown cell loss • Cognitive impairment as early as 4 months prior to formation of plaques and tangles	(Oddo et al., 2003)
Tg4510	• MAPT (P301L) • Transgene downstream of TRE and driven by tTA under the control of CaMKII-α promoter	• No amyloid plaques • Tangles present at 4 months • Significant neuronal and brain volume loss • Cognitive impairment starting as early as 2.5 months	(Santacruz et al., 2005)

Supplemental References:

Chishti, M.A., Yang, D.S., Janus, C., Phinney, A.L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001). Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. *276*, 21562–21570.

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science *274*, 99–102.

Mucke, L., Masliah, E., Yu, G.Q., Mallory, M., Rockenstein, E.M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. (2000). High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. Journal of Neuroscience *20*, 4050–4058.

Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., Metherate, R., Mattson, M.P., Akbari, Y., and LaFerla, F.M. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron *39*, 409–421.

Radde, R., Bolmont, T., Kaeser, S.A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M.E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006). Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. *7*, 940–946.

Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science *309*, 476–481.